Stroke patients show higher rate of recovery from MultiStem® cell therapy studied at University Hospitals Case Medical Center

Wednesday, February 24, 2016
CLEVELAND – Data presented by the biotech company Athersys indicates that stroke patients treated by an adult stem cell therapy called MultiStem® did significantly better than others who received a placebo one year after treatment.  The results are from a Phase 2 study involving clinical sites in the United States and the United Kingdom, including University Hospitals Case Medical Center. The study examined the safety and effectiveness of the new therapy developed for the treatment of ischemic stroke.  The data were presented Feb. 17 at the 2016 International Stroke Conference in Los Angeles.
Of the 65 patients treated with MultiStem®, 23.1 percent achieved a complete or near full recovery from their stroke after one year.  Only 8.2 percent of the 61 placebo patients achieved that level of recovery.  Patients who received the cell therapy within 36 hours after the onset of stroke did even better, with 29 percent of those 31 patients achieving an excellent outcome.
Cathy Sila, MD, Director of the Comprehensive Stroke Center at UH Case Medical Center, and Professor of Neurology at Case Western Reserve University, was the principal investigator of the study at UH Case Medical Center.

Download full release

<< Back

You must be logged in to view this item.


This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.